Clipping of news on Brazilian Culture, Law and Citizenship
10/31/2016
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Transparent image
National Program for the Verification of the Quality of Medicines informs that samples analyzed in this second semester have achieved satisfactory results
Posted: 10/27/2016 18:41
Last Modified: 10/27/2016 18:47
All the analyzes of the National Program for the Verification of the Quality of Medicines (Proveme) completed in the second half of 2016 have achieved, to date, satisfactory results.
Proveme, coordinated by ANVISA, evaluates the physical and chemical characteristics of generic, similar and reference medicines through the official laboratories of the National Network of Sanitary Surveillance Laboratories (RNLVISA).
An International Technical Cooperation agreement signed between Anvisa and the United Nations Development Program (UNDP), last July 20, defined the scope of the Proveme. Under the terms of the agreement, which will last 18 months, 1,800 samples of drugs will be analyzed.
The partnership between Anvisa and UNDP for the execution of the Proveme also involves the Secretariats of Health, 13 central laboratories of Health (Lacen), the National Institute of Quality Control in Health (INCQS-Fiocruz) and state and municipal Surveillance coordinations Sanitary Visa coordinators conduct the collection of drug samples. The drugs that will be evaluated in the Proveme are the most notified by technical complaints and quality deviation, those made available by the program Aqui Tem Farmácia Popular, the most consumed by the Brazilian population, as well as those present in other programs of the Ministry of Health.
Anvisa instituted Proveme in 2001. Since its inception, the Program has been responsible for the analysis of more than three thousand drugs and the results defined various sanitary actions, such as suspension of sale and use, changes in registration, inspection actions, adoption Of corrective actions by the manufacturers and introduction of sanitary administrative processes.
For the coming months, it is expected that laboratory tests will be performed on about 100 different drug samples per month. In the case of unsatisfactory results, the drug will be promptly banned until screening tests are performed.
Source: Anvisa
Our news is removed in full from our partners' websites. For this reason, we can not change the content of these even in cases of typos.
This article was translated by an automatic translation system, and was therefore not reviewed by people.